Considering that SVIP is an ERAD inhibitor and found to be negatively regulated by R1881 treatment in LNCaP cells21, we tested the regulation of the ERAD pathway using LNCaP prostate cancer cell line using the synthetic androgen, R1881. This evidence concerns the gene SVIP and Familial prostate cancer.